Insomnia is among the most common complaints in neurologic practice, affecting up to 30% of adults at some point. The pharmacology of insomnia treatment has evolved from older sedative-hypnotics (benzodiazepines, barbiturates) to safer “z-drugs,” dual orexin receptor antagonists, melatonin agonists, and emerging targeted therapies. The neurologist must navigate insomnia in the context of underlying neurologic disease (PD, MS, post-stroke, dementia, RBD), comorbid mood disorders, and patient-specific risk factors. This page covers the modern pharmacotherapy of insomnia.

Approach to Insomnia

Cognitive Behavioral Therapy for Insomnia (CBT-I)

  • First-line for chronic insomnia.
  • Most effective long-term intervention.
  • Components: stimulus control, sleep restriction, cognitive restructuring, relaxation training, sleep hygiene.
  • App-based (e.g., Sleepio, CBT-I Coach).
  • Pharmacotherapy is an adjunct, not replacement.

Address Underlying Contributors

  • Pain.
  • Depression, anxiety.
  • Sleep apnea (screen with STOP-BANG or Epworth).
  • Restless legs syndrome.
  • Medication-induced (corticosteroids, stimulants, antidepressants, beta-blockers, caffeine).
  • Medical conditions (CHF, prostatic hypertrophy, hyperthyroidism).
  • Substance use.

Hypnotic Drug Classes

Z-Drugs (Non-Benzodiazepine GABA-A Modulators)

  • Zolpidem (Ambien): 5-10 mg HS; rapid onset; selective α1; immediate-release vs CR.
  • Zaleplon (Sonata): 10-20 mg HS; very short half-life; can take in middle of night.
  • Eszopiclone (Lunesta): 1-3 mg HS; longer half-life; can take for 6-8 hour sleep window.
  • Side effects: drowsy hangover (especially CR forms), parasomnias (sleep-walking, eating, driving — black box), anterograde amnesia, falls in elderly.
  • FDA warning: lower starting doses in women (different PK).
  • Lower dependence/tolerance risk than benzodiazepines.

Benzodiazepines

  • Triazolam: short half-life; insomnia onset.
  • Temazepam, oxazepam: intermediate; less interaction; preferred for sleep.
  • Diazepam, lorazepam, clonazepam: longer-acting; daytime carryover.
  • Side effects: cognitive impairment, falls, dependence, tolerance, withdrawal seizures.
  • BEERS criteria avoid in elderly.
  • Reserve for short-term; avoid chronic use.

Dual Orexin Receptor Antagonists (DORAs)

  • Suvorexant (Belsomra): 10-20 mg HS.
  • Lemborexant (Dayvigo): 5-10 mg HS.
  • Daridorexant (Quviviq): 25-50 mg HS.
  • Mechanism: block orexin/hypocretin → promote sleep without GABA modulation.
  • Advantages: more favorable dependence/tolerance profile than benzodiazepines or z-drugs; preserved sleep architecture; less morning sedation. They are not risk-free, however — they remain controlled substances (Schedule IV) and carry abuse/dependence warnings in FDA labeling.
  • Side effects: dose-dependent next-day sedation, vivid dreams, headache.
  • Cataplexy reports (rare); avoid in narcolepsy.
  • Increasingly first-line pharmacologic option for chronic insomnia.

Melatonin Receptor Agonists

  • Ramelteon (Rozerem): 8 mg HS; MT1/MT2 selective; not a controlled substance; no abuse potential; safer in elderly.
  • Tasimelteon (Hetlioz): for non-24-hour sleep-wake disorder (blind individuals); circadian rhythm reset.
  • Melatonin (over-the-counter): variable quality; effective for jet lag, shift work, some elderly with circadian dysrhythmia; standard doses 0.5-5 mg.

Sedating Antidepressants

  • Trazodone: 25-100 mg HS; commonly used off-label; reduces middle-of-night awakenings.
  • Mirtazapine: 7.5-30 mg HS; sleep + mood + appetite stimulation; useful in depression with insomnia.
  • Doxepin (low-dose, Silenor): 3-6 mg HS; FDA-approved for insomnia; histaminergic effect; less anticholinergic at low doses.
  • Avoid amitriptyline for insomnia in elderly (anticholinergic).

Sedating Antipsychotics

  • Quetiapine, olanzapine: AVOID off-label for insomnia — significant side effects, mortality risk in dementia.
  • Reserve for documented psychotic or mood indication.

Antihistamines

  • Diphenhydramine, doxylamine: over-the-counter.
  • Anticholinergic; cognitive concerns in elderly.
  • Tolerance develops rapidly.
  • Generally NOT recommended; avoid in elderly.

Choice of Hypnotic

Sleep-Onset Insomnia

  • Ramelteon (mild cases).
  • Zaleplon (short half-life).
  • Zolpidem (immediate release).

Sleep-Maintenance Insomnia

  • Eszopiclone.
  • Zolpidem CR.
  • DORAs (suvorexant, lemborexant, daridorexant).
  • Doxepin low-dose.
  • Trazodone.

With Comorbid Mood Disorder

  • Mirtazapine (depression).
  • Doxepin (depression).
  • Trazodone.

Elderly

  • Ramelteon (safest).
  • Low-dose doxepin.
  • Trazodone.
  • DORAs (well-tolerated).
  • AVOID: benzodiazepines (BEERS), older z-drugs (parasomnias), anticholinergics (cognition).

Specific Sleep Disorders

Obstructive Sleep Apnea (OSA)

  • CPAP first-line.
  • Modafinil, armodafinil: residual sleepiness despite CPAP.
  • Solriamfetol: alternative for residual EDS in OSA.
  • NO benzodiazepines (worsen OSA).

REM Sleep Behavior Disorder

  • Clonazepam: traditional; effective; sedation, falls.
  • Melatonin (3-12 mg): alternative; less side effects; often preferred elderly.
  • Address bedroom safety.
  • RBD is a prodromal marker for α-synucleinopathies.

Narcolepsy

  • Modafinil, armodafinil, methylphenidate, amphetamines: stimulants for daytime sleepiness.
  • Sodium oxybate (Xyrem, Xywav): GHB; reduces cataplexy; promotes sleep; REMS program.
  • Pitolisant (Wakix): H3 antagonist; FDA-approved; wakefulness + cataplexy reduction.
  • Solriamfetol (Sunosi): wakefulness for OSA-related EDS, narcolepsy.
  • Cataplexy: SSRIs, SNRIs, TCAs (suppress REM-related cataplexy); sodium oxybate.

Restless Legs Syndrome

  • Iron replacement (ferritin <75-100).
  • α2δ ligands (gabapentin, pregabalin): first-line.
  • Dopamine agonists (pramipexole, ropinirole, rotigotine): secondary; augmentation risk.
  • Opioids: refractory severe.

Circadian Rhythm Disorders

  • Delayed sleep-wake phase: morning bright light + evening melatonin.
  • Advanced sleep-wake phase: evening bright light.
  • Non-24-hour sleep-wake disorder: tasimelteon, melatonin.
  • Shift work disorder: timing of sleep, light exposure; modafinil for residual EDS.

Sleep Issues in Specific Neurologic Conditions

Parkinson Disease

  • Multifactorial: medications, motor symptoms, RBD, nocturia, anxiety.
  • Optimize nighttime levodopa.
  • Address depression, anxiety.
  • RBD: melatonin or clonazepam.
  • EDS: modafinil; reduce dopamine agonist if contributing.

Multiple Sclerosis

  • Fatigue often confused with sleepiness.
  • Modafinil for fatigue.
  • Treat depression, pain, RLS.
  • Sleep apnea increasingly recognized in MS.

Post-Stroke

  • Sleep apnea screening important.
  • Depression treatment.
  • Insomnia after stroke: cognitive, behavioral, and pharmacologic approaches.

Dementia

  • Avoid: benzodiazepines, z-drugs (paradoxical agitation, falls), anticholinergics.
  • Melatonin: first choice for many.
  • Trazodone low-dose.
  • Mirtazapine.
  • Address sundowning patterns.

Epilepsy

  • Many ASMs sedating.
  • Sleep-related epilepsy syndromes (BECTS, GEFS+).
  • Insomnia common; treat carefully (some ASMs interact with hypnotics).

Insomnia in Children and Adolescents

  • Behavioral interventions first.
  • Melatonin most studied; relatively safe.
  • Pediatric-specific dosing.
  • Diphenhydramine: NOT recommended (paradoxical agitation in some).

Pregnancy

  • Behavioral interventions emphasized.
  • Magnesium acceptable.
  • Doxylamine: pregnancy class A (for nausea + sleep).
  • Limited data on z-drugs.

Discontinuation Considerations

  • Long-term hypnotic use: taper slowly to avoid rebound insomnia and withdrawal.
  • CBT-I particularly useful during taper.
  • Some patients require maintenance therapy.

🔍 Did You Know?

The development of dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, and daridorexant — represents a mechanistically novel approach to insomnia treatment that builds directly on Nobel Prize-winning research into orexin/hypocretin neurons. The orexin system, located in the lateral hypothalamus, maintains wakefulness through projections to multiple arousal centers; orexin deficiency causes narcolepsy. The therapeutic insight was elegant: blocking orexin receptors should produce physiological sleep without the broader GABA-A modulation of traditional sedatives. The result is hypnotics that: (1) maintain normal sleep architecture (preserved REM, slow-wave sleep); (2) produce no tolerance or dependence; (3) reduce next-day sedation compared to z-drugs and benzodiazepines; (4) have a unique mechanism that complements traditional approaches. The clinical impact: DORAs have become first-line pharmacologic options for chronic insomnia in many adult and elderly populations. The lesson generalizes: understanding the neuroscience of sleep-wake regulation has produced more targeted therapeutics, and the same principle is being applied to other CNS conditions through specific neurotransmitter system modulation rather than broad sedation. For practicing neurologists, DORAs offer an alternative when patients are concerned about dependence, when they have failed traditional hypnotics, or when sleep architecture preservation matters (e.g., epilepsy patients on multiple sedatives). The lesson for drug development is that even well-established therapeutic targets (sleep) can have mechanistically novel approaches.

Pitfalls and Pearls

  • CBT-I first-line for chronic insomnia.
  • Z-drugs: zolpidem, zaleplon, eszopiclone; parasomnias black box; falls.
  • Benzodiazepines: dependence, tolerance; avoid in elderly.
  • DORAs (suvorexant, lemborexant, daridorexant): more favorable dependence/tolerance profile than benzos/z-drugs; preserved sleep architecture. Still Schedule IV with abuse/dependence warnings.
  • Ramelteon: MT1/MT2; non-controlled; safe in elderly.
  • Low-dose doxepin: FDA-approved; antihistamine effect at low dose.
  • Trazodone: commonly off-label.
  • Mirtazapine: dual mood + sleep + appetite.
  • Avoid: quetiapine off-label, anticholinergics (especially elderly).
  • RBD: clonazepam or melatonin; prodromal synucleinopathy.
  • OSA: CPAP first-line; AVOID benzodiazepines.
  • Narcolepsy: stimulants, sodium oxybate, pitolisant.
  • RLS: iron, gabapentinoids, dopamine agonists (augmentation).
  • Pediatric: melatonin most studied; behavioral first.
  • Pregnancy: doxylamine; magnesium.
  • Dementia: melatonin, trazodone; AVOID benzodiazepines, z-drugs.

References

  1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. J Clin Sleep Med. 2017;13(2):307-349.
  2. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline. Ann Intern Med. 2016;165(2):125-133.
  3. Mignot E. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739-752.
  4. Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14(8):1399-1408.
  5. Sakai N, Sasaki S, Tomita N, Yokoyama M. Pharmacology of the dual orexin receptor antagonists. Front Neurol. 2023;14:1163-1175.